Lixte Historical Income Statement
| LIXTW Stock | USD 0.03 0.0002 0.71% |
Historical analysis of Lixte Biotechnology income statement accounts such as Total Operating Expenses of 2.7 M can show how well Lixte Biotechnology Holdings performed in making a profits. Evaluating Lixte Biotechnology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Lixte Biotechnology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Lixte Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lixte Biotechnology is a good buy for the upcoming year.
Lixte |
About Lixte Income Statement Analysis
Lixte Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Lixte Biotechnology shareholders. The income statement also shows Lixte investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Lixte Biotechnology Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Lixte Biotechnology. It is also known as Lixte Biotechnology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Lixte Biotechnology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Lixte Biotechnology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lixte Biotechnology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At this time, Lixte Biotechnology's Interest Expense is fairly stable compared to the past year. EBITDA is likely to climb to 3,367 in 2024, despite the fact that Operating Income is likely to grow to (4.8 M).
| 2023 | 2024 (projected) | Interest Income | 20.5K | 12.4K | Gross Profit | 180K | 160K |
Lixte Biotechnology income statement Correlations
Click cells to compare fundamentals
Lixte Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lixte Biotechnology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 49.7K | 3.7K | 7.4K | 8.9K | 16.2K | 17.0K | |
| Other Operating Expenses | 2.5M | 3.3M | 6.7M | 6.3M | 5.1M | 2.7M | |
| Operating Income | (2.5M) | (3.3M) | (6.7M) | (6.3M) | (5.1M) | (4.8M) | |
| Ebit | (2.5M) | (3.3M) | (6.7M) | (6.3M) | (5.1M) | (4.8M) | |
| Ebitda | (2.5M) | 1.6K | (8.0K) | (1.1K) | 3.2K | 3.4K | |
| Total Operating Expenses | 2.5M | 3.3M | 6.7M | 6.3M | 5.1M | 2.7M | |
| Net Income | (2.4M) | (3.3M) | (6.7M) | (6.3M) | (5.1M) | (4.8M) | |
| Income Tax Expense | (49.7K) | (1.6K) | 6.8K | (7.8K) | (5.1K) | (4.8K) | |
| Depreciation And Amortization | 2.5K | 3.3M | 6.7M | 6.3M | 5.1M | 5.3M | |
| Selling General Administrative | 1.7M | 2.0M | 5.0M | 5.0M | 4.2M | 4.4M | |
| Research Development | 820.9K | 1.2M | 1.7M | 1.3M | 898.1K | 1.0M | |
| Income Before Tax | (2.4M) | (3.3M) | (6.7M) | (6.3M) | (5.1M) | (4.8M) | |
| Total Other Income Expense Net | 49.7K | 1.6K | (8.0K) | (1.1K) | 3.2K | 3.4K | |
| Interest Income | 49.7K | 1.6K | 626.0 | 11.2K | 20.5K | 12.4K | |
| Net Income Applicable To Common Shares | (1.8M) | (2.1M) | (2.4M) | (3.3M) | (2.9M) | (3.1M) | |
| Net Interest Income | 49.7K | 1.6K | (6.8K) | 2.3K | 10.8K | 7.3K | |
| Net Income From Continuing Ops | (2.4M) | (3.3M) | (6.7M) | (6.3M) | (5.7M) | (6.0M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.